GlassScriptPhysician profile
Janardhan Srinivasan
NPI 1598099376
$10,177.84
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,416 · 2020: $1,724 · 2021: $229 · 2022: $321 · 2023: $4,448 · 2024: $40.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $4,139 · Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $4,138.89 |
| Food and Beverage | $349.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $4,242.39 | 2021-2023 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $2,937.48 | 2019-2024 | Jot Dx, Diamondback Peripheral |
| Penumbra, INC. | $1,279.86 | 2019 | |
| Boston Scientific Corporation | $386.49 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $226.04 | 2019-2022 | |
| Medtronic, INC. | $167.21 | 2021-2023 | Onyx Frontier |
| Cardiovascular Systems INC. | $149.05 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $118.97 | 2019 | |
| Teleflex LLC | $106.28 | 2023 | Twin-Pass |
| Amgen INC. | $81.62 | 2019-2020 | |
| Chiesi USA, INC. | $76.81 | 2019-2022 | |
| Biotronik INC. | $70.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $66.82 | 2019 | |
| Medtronic Vascular, INC. | $60.87 | 2019 | |
| W. L. Gore & Associates, INC. | $39.77 | 2023 | Gore Viabahn Vbx Balloon Expandable Endo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.86 | 2022 | |
| Cordis US Corp. | $26.37 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $24.10 | 2024 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $19.22 | 2019 | |
| Astellas Pharma US INC | $15.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.86 | 2020 | |
| Terumo Medical Corporation | $14.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.94 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janardhan Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.